Evaxion Biotech (EVAX) said Thursday that new preclinical data showed its experimental acute myeloid leukemia vaccine, EVX-04, was able to kill target cancer cells.

The company said all endogenous retroviral antigens included in the vaccine triggered targeted immune responses in both mouse studies and human cell experiments across a range of immune profiles.

Evaxion added that it is continuing preclinical development of EVX-04 while preparing the regulatory filings needed to begin clinical testing.